Latest Healthcare Research Reports

Tag: Analysis And Research Report_x000D_

  • Global Deoxyribonucleic Acid (DNA) Manufacturing Market Growth Prospects and Strategic Opportunities Through 2029

    Global Deoxyribonucleic Acid (DNA) Manufacturing Market Growth Prospects and Strategic Opportunities Through 2029

    Uncover key drivers, emerging technologies, and competitive movements shaping the deoxyribonucleic acid (dna) manufacturing market from 2025–2034 with trusted insights from The Business Research Company

    What Are The Market Size Estimates For The Deoxyribonucleic Acid (DNA) Manufacturing Market?

    The deoxyribonucleic acid (DNA) manufacturing market has experienced significant growth in recent years. This market is expected to expand from $4.77 billion in 2024 to $5.58 billion in 2025, achieving a compound annual growth rate (CAGR) of 16.9%. The past growth can be linked to factors such as the emergence of genomics-based research, the expansion of biotechnology and biopharma industries, an increase in contract manufacturing organizations (CMOs), broader adoption of CRISPR and gene editing applications, and government financial backing and programs.

    The deoxyribonucleic acid (DNA) manufacturing market is projected to experience substantial expansion in the coming years. By 2029, its valuation is anticipated to reach $10.28 billion, demonstrating a compound annual growth rate (CAGR) of 16.5%. This growth during the forecast period is primarily driven by factors such as the broadening of cell and gene therapy development, a rise in drug discovery efforts, heightened biodefense initiatives, increased expenditures on pandemic readiness, and the worldwide integration of biomanufacturing supply networks. Key trends anticipated during this period encompass the incorporation of next-generation sequencing (NGS), progress in mRNA and DNA vaccine development, innovations in long-read and high-fidelity synthesis techniques, the application of automation and robotics in DNA production, and the emergence of next-generation enzymatic DNA synthesis (EDS).

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27272&type=smp

    Which Growth Drivers Are Shaping The Deoxyribonucleic Acid (DNA) Manufacturing Market Outlook?

    The deoxyribonucleic acid (DNA) manufacturing market is projected to expand due to the escalating need for gene therapies. Gene therapies encompass techniques designed to modify or replace faulty genes to treat or prevent diseases. This heightened demand for gene therapies stems from the growing incidence of genetic conditions such as cystic fibrosis, sickle cell anemia, and certain types of inherited blindness. Deoxyribonucleic acid (DNA) manufacturing is crucial for gene therapies, as it supplies the necessary high-quality, custom DNA sequences for developing and delivering therapeutic genes capable of correcting or substituting erroneous genetic material in patients. For example, in August 2024, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported that the population in the UK eligible for gene therapy treatment is anticipated to increase from 2,500 in 2021 to approximately 10,000 annually by 2028. Consequently, the surging demand for gene therapies is propelling the growth of the deoxyribonucleic acid (DNA) manufacturing market.

    What Are The Primary Segmentation Parameters In The Deoxyribonucleic Acid (DNA) Manufacturing Market?

    The deoxyribonucleic acid (DNA) manufacturing market covered in this report is segmented

    1) By Type: Plasmid Deoxyribonucleic Acid (DNA), Synthetic Deoxyribonucleic Acid (DNA), Gene Synthesis, Oligonucleotide Synthesis

    2) By Grade: Good Manufacturing Practices (GMP) Grade, Research And Development Grade

    3) By Application: Cell And Gene Therapy, Vaccines, Oligonucleotide-Based Drugs, Other Applications

    4) By End-Use: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations

    Subsegments:

    1) By Plasmid Deoxyribonucleic Acid (DNA): GMP-Grade Plasmid DNA, Non-GMP-Grade Plasmid DNA, High Copy Number Plasmids, Low Copy Number Plasmids, Bacterial Fermentation-Based Plasmid Production, Transfection-Grade Plasmid DNA

    2) By Synthetic Deoxyribonucleic Acid (DNA): Enzymatic DNA Synthesis, Chemical DNA Synthesis, Long DNA Fragments, Short DNA Fragments, Single-Stranded Synthetic DNA, Double-Stranded Synthetic DNA

    3) By Gene Synthesis: Custom Gene Synthesis, Standard Gene Synthesis, Complex Gene Constructs, Codon Optimization Services, Gene Library Synthesis

    4) By Oligonucleotide Synthesis: DNA Oligonucleotides, Modified Oligonucleotides, Long Oligonucleotides, PCR Primers, SiRNA And Antisense Oligos, Adapter And Linker Oligos

    Which Emerging Trends Are Reshaping The Deoxyribonucleic Acid (DNA) Manufacturing Market Landscape?

    Major companies within the DNA manufacturing market are concentrating on developing innovative approaches, such as GMP-grade plasmid DNA production, to enhance the quality, safety, and scalability of gene and cell therapy applications. GMP-grade plasmid DNA production refers to the manufacture of plasmid DNA under Good Manufacturing Practice (GMP) conditions, which are regulatory guidelines ensuring the quality, safety, and consistency of biopharmaceutical products. For instance, in April 2025, ProBio Genomics Inc., a US-based contract development and manufacturing organization (CDMO), launched GMP Plasmid DNA Manufacturing Services in Hopewell, offering in-house analytical testing, method development, and project management. This service provides unique features, including in-house process development, analytical testing, method development, and project management, thereby eliminating the need for multiple suppliers and speeding up development timelines. The service ensures high-quality output with at least 85% supercoiled plasmid DNA content while minimizing contamination risks. ProBio also offers GMP-like plasmids with a four-week delivery timeline and full GMP-grade plasmids within three months.

    Which Organizations Are At The Forefront Of The Deoxyribonucleic Acid (DNA) Manufacturing Market?

    Major companies operating in the deoxyribonucleic acid (DNA) manufacturing market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Kaneka Corporation, Catalent Inc., Charles River Laboratories International Inc., WuXi Biologics Inc., AGC Biologics Inc., Integrated DNA Technologies Inc., GenScript Biotech Corporation, Takara Bio USA Inc., Twist Bioscience Corp., Ajinomoto Bio-Pharma Services, OriGene Technologies Inc., DNA Script SAS, Eurofins Genomics LLC, Touchlight Genetics Ltd., Elegen Inc., VGXI Inc., PlasmidFactory GmbH & Co. KG.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/deoxyribonucleic-acid-dna-manufacturing-global-market-report

    Which Region Holds The Greatest Opportunity For Deoxyribonucleic Acid (DNA) Manufacturing Market Expansion?

    North America was the largest region in the deoxyribonucleic acid (DNA) manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the deoxyribonucleic acid (DNA) manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=27272&type=smp

    Browse Through More Reports Similar to the Global Deoxyribonucleic Acid (DNA) Manufacturing Market 2025, By The Business Research Company

    Electronic Equipment Repair Service Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/electronic-equipment-repair-service-global-market-report

    Industrial Maintenance Services Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/industrial-maintenance-services-global-market-report

    Specialty Lighting Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/specialty-lighting-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Central Nervous System Therapeutics Market Trends 2025–2029: Regional Outlook and Sizing Analysis

    Global Central Nervous System Therapeutics Market Trends 2025–2029: Regional Outlook and Sizing Analysis

    Uncover key drivers, emerging technologies, and competitive movements shaping the central nervous system therapeutics market from 2025–2034 with trusted insights from The Business Research Company

    What Is The Present And Forecasted Size Of The Central Nervous System Therapeutics Market?

    The central nervous system therapeutics market has experienced robust expansion in recent years. Its value is projected to increase from $123.53 billion in 2024 to $134.99 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.3%. The growth observed in the past can be ascribed to a surge in neurological disorders, increased mental health awareness, a rise in research and development endeavors, growing demand for personalized medicine, and an increase in trade agreements.

    The market for central nervous system therapeutics is projected to experience robust expansion over the coming years. This market is anticipated to reach $190.07 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.9%. This anticipated growth during the forecast period stems from factors such as the rising incidence of CNS disorders, a heightened emphasis on therapeutic development, the growing occurrence of conditions like Alzheimer’s, an expanding elderly demographic, and a greater need for efficacious treatments. Key developments expected in this period encompass the application of artificial intelligence in diagnostics, progress in formulating antidepressant drugs, enhanced drug delivery methods, significant strides in neurology, and the identification of new biomarkers.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp

    What Underlying Factors Are Supporting The Central Nervous System Therapeutics Market Growth?

    The escalating occurrence of mental health conditions is anticipated to drive the expansion of the central nervous system therapeutics market. These conditions encompass various states impacting an individual’s thoughts, emotions, actions, or mood, including depression, anxiety disorders, schizophrenia, and bipolar disorder. The increasing incidence of mental health disorders stems from heightened exposure to prolonged stress, which can impair emotional regulation, diminish coping strategies, and foster issues like anxiety, depression, and burnout. Central Nervous System (CNS) treatments alleviate mental health disorders by focusing on brain chemicals and neural pathways associated with mood, behavior, and cognition. As an illustration, in December 2025, a report from the Bristol City Council, a UK-based local government authority, noted that in Bristol, 66,815 patients aged 18 and over were logged on GP practice depression registers in 2022/23, representing a 6.0% increase from 2021/22. Consequently, the growing prevalence of mental health disorders is propelling the central nervous system therapeutics market forward.

    How Does The Central Nervous System Therapeutics Market Differ By Segment?

    The central nervous system therapeutics market covered in this report is segmented

    1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes

    2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases

    3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

    4) By Application: Hospital, Clinic, Homecare, Other Applications

    Subsegments:

    1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics

    2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents

    3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids

    4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives

    5) By Pain Relievers: Opioid Analgesics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief, Topical Agents

    6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

    What New Opportunities Are Emerging From Trends In The Central Nervous System Therapeutics Market?

    Leading companies in the central nervous system therapeutics market are concentrating on developing innovative solutions, such as capsid engineering, to improve targeted gene delivery, therapeutic effectiveness, and blood-brain barrier penetration for better treatment of neurological disorders. Capsid engineering involves the modification and optimization of the protein shell, or capsid, of viral vectors, typically adeno-associated viruses (AAVs), utilized in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, launched coAAV CSF 01, a novel adeno-associated virus (AAV) specifically for central nervous system (CNS) delivery, employing their proprietary ALIGATER platform. This new solution demonstrated significantly enhanced transduction efficiency and safety compared to AAV9. When delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Remarkably, expression levels equivalent to AAV9 were attained with just one-fifth of the dose, highlighting its superior potency. Additionally, the vector showed substantially reduced off-target expression in peripheral organs such as the liver while maintaining a favorable safety profile, including preserved peripheral nerve integrity. These results underscore the vector’s potential to enhance CNS gene therapy outcomes with improved precision and lower systemic risk.

    Who Are The Global Leaders Steering The Central Nervous System Therapeutics Market Forward?

    Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Kyverna Therapeutics Inc., Immunic Inc., LEXEO Therapeutics Inc., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., and Assertio Holdings Inc.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report

    Which Region Is Likely To Register The Fastest Growth In The Central Nervous System Therapeutics Market?

    North America was the largest region in the central nervous system therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=27249&type=smp

    Browse Through More Reports Similar to the Global Central Nervous System Therapeutics Market 2025, By The Business Research Company

    Coronavirus Current Therapy Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report

    Critical Illness Insurance Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/critical-illness-insurance-global-market-report

    Embedded Insurance Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/embedded-insurance-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • What Is The Predicted Revenue Outlook For The Global Cell Culture Media Market For Regenerative Medicines Market To Surpass $8.24 Billion?

    What Is The Predicted Revenue Outlook For The Global Cell Culture Media Market For Regenerative Medicines Market To Surpass $8.24 Billion?

    Uncover key drivers, emerging technologies, and competitive movements shaping the cell culture media market for regenerative medicines market from 2025–2034 with trusted insights from The Business Research Company

    How Is The Cell Culture Media Market For Regenerative Medicines Market Expected To Grow In Terms Of Size?

    The cell culture media market for regenerative medicines has expanded significantly in recent years. It is projected to grow from $4.68 billion in 2024 to $5.26 billion in 2025, achieving a compound annual growth rate (CAGR) of 12.3%. This historical growth can be primarily attributed to the increasing demand for regenerative medicines, such as cell therapies and tissue engineering. Other contributing factors include the rising prevalence of chronic diseases driving research needs, an increase in biopharmaceutical production requiring advanced culture systems, greater government funding and favorable regulations supporting life sciences, and improvements in media formulations and cell culture efficiency.

    The cell culture media market for regenerative medicines is anticipated to experience substantial growth in the upcoming years. Its size is expected to reach $8.24 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 11.9%. This expansion during the forecast period is driven by factors such as the increasing demand for regenerative therapies and biopharmaceuticals, rising investments in research and development for regenerative medicine, the growing adoption of serum-free and chemically defined media, increased government support and favorable regulations, and the rising need for scalable and automated cell culture production systems. Significant trends during this period will include advancements in serum-free and xeno-free media, the development of automated and high-throughput cell culture systems, innovations in personalized and precision therapies, progress in stem cell and regenerative medicine applications, and the creation of custom and chemically defined formulations.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27241&type=smp

    What Market Forces Are Contributing To The Growth Of The Cell Culture Media Market For Regenerative Medicines Market?

    The increasing emphasis on personalized medicine is anticipated to stimulate the expansion of the cell culture media market for regenerative medicines. This medical approach involves tailoring treatment and prevention plans according to an individual’s unique genetic profile, environment, and lifestyle. The heightened attention on personalized medicine stems from a greater demand for targeted therapies for rare and intricate diseases, a demand that is escalating due to advancements in genomic research and availability of precise diagnostic tools. The cell culture media market for regenerative medicines facilitates personalized medicine through the creation of specialized media, specifically designed to cultivate patient-specific cells for bespoke regenerative therapies. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the FDA cleared 16 novel personalized treatments for patients with rare diseases in 2023, an increase from 6 in 2022. Consequently, the expanding focus on personalized medicine is a key factor propelling the growth of the cell culture media market for regenerative medicines.

    How Is The Cell Culture Media Market For Regenerative Medicines Market Segmented Across Key Categories?

    The cell culture media market for regenerative medicines market covered in this report is segmented

    1) By Type: Liquid Media, Semi-Solid And Solid Media

    2) By Application: Tissue Engineering, Gene Therapy, Stem Cell Research, Cell Therapy, Drug Discovery And Development, Other Applications

    3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Hospitals And Diagnostic Laboratories, Cell Banks, Other End Users

    Subsegment:

    1) By Liquid Media: Basal Media, Serum-Free Media, Chemically Defined Media, Protein-Free Media, Specialty Media

    2) By Semi-Solid And Solid Media: Agar-Based Media, Gelatin-Based Media, Collagen-Based Media, Methylcellulose Media, Other Hydrogel-Based Media

    What Key Trends Are Driving Growth In The Cell Culture Media Market For Regenerative Medicines Market?

    Major companies operating in the `cell culture media market for regenerative medicines market` are focusing on developing innovative products, such as `animal-component-free mediums`, to enhance cell growth consistency, improve safety, meet regulatory requirements, and support scalable clinical manufacturing. An `animal-component-free medium` is a `cell culture solution` formulated without any materials derived from animals, designed to improve consistency, safety, and regulatory compliance in research and therapeutic applications. For instance, in `May 2023`, `Lonza Group AG`, a `Switzerland`-based life sciences company, introduced `TheraPEAK T-VIVO Cell Culture Medium`, a novel chemically defined, `animal-component-free formulation` designed to optimize `CAR T-cell manufacturing`. By eliminating reliance on animal or human serum—traditionally associated with high variability, risk of adventitious agents, and the need for extensive safety testing and batch stockpiling—the new medium enhances process consistency, improves control, and streamlines regulatory compliance, ultimately reducing costs and accelerating time-to-market. Delivering high performance without the need for human serum supplementation, `TheraPEAK T-VIVO` marks a strategic advancement in Lonza’s mission to expedite and simplify cell therapy commercialization for its global customer base.

    Who Are The Major Stakeholders Operating In The Cell Culture Media Market For Regenerative Medicines Market?

    Major companies operating in the cell culture media market for regenerative medicines market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton Dickinson and Company, GE Healthcare Technologies Inc., Corning Incorporated, Avantor Inc., Lonza Group AG, Cytiva Life Sciences, Sartorius AG, Bio-Techne Corporation, Miltenyi Biotec B.V. & Co. KG, STEMCELL Technologies Inc., FUJIFILM Irvine Scientific Inc., Takara Bio Inc., HiMedia Laboratories Private Limited, PromoCell GmbH, Cell Biologics Inc., Xcell Biosciences Inc., and Eklavya Biotech Pvt Ltd.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/cell-culture-media-market-for-regenerative-medicines-global-market-report

    How Do Regional Dynamics Influence The Cell Culture Media Market For Regenerative Medicines Market Performance?

    North America was the largest region in the cell culture media market for regenerative medicines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell culture media market for regenerative medicines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=27241&type=smp

    Browse Through More Reports Similar to the Global Cell Culture Media Market For Regenerative Medicines Market 2025, By The Business Research Company

    Real Time Payments Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/real-time-payments-market

    Digital Payments Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/digital-payments-global-market-report

    Bitcoin Payments Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/bitcoin-payments-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Cancer Gene Therapy Market Trends and Future Outlook to 2029

    Global Cancer Gene Therapy Market Trends and Future Outlook to 2029

    Uncover key drivers, emerging technologies, and competitive movements shaping the cancer gene therapy market from 2025–2034 with trusted insights from The Business Research Company

    What Is The Predicted Market Size Of The Cancer Gene Therapy Industry By 2029?

    The cancer gene therapy market size has seen substantial growth recently. It is anticipated to expand from $3.61 billion in 2024 to $4.21 billion in 2025, at a compound annual growth rate (CAGR) of 16.6%. The historical expansion of this market can be attributed to heightened awareness of oncovirus-related cancers, an uptick in collaborations between biotechnology firms and academic bodies, increased clinical trial participation for early-phase gene therapies, a rising demand for ex vivo modified cell therapies, and a notable rise in strategic licensing deals for gene therapy platforms.

    The cancer gene therapy market size is expected to undergo substantial growth over the next few years. It is projected to expand to $7.67 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 16.2%. This expansion during the forecast period can be attributed to an increased focus on non-viral delivery systems, wider availability of companion diagnostics, rising interest in off-the-shelf allogeneic cell therapies, the increasing reach of contract development & manufacturing organizations (CDMOs), and advancements in synthetic biology that enable customizable gene circuits. Key trends anticipated in this period include developments in non-viral gene delivery platforms, sophisticated manufacturing automation for gene therapy production, the creation of synthetic promoters for cancer-specific expression, innovations in intratumoral gene therapy administration, and the development of multiplexed gene modulation strategies.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp

    Which Factors Are Steering Growth In The Cancer Gene Therapy Market?

    The rising occurrence of cancer is anticipated to drive expansion in the cancer gene therapy market in the future. Cancer is defined as an illness marked by the uncontrolled proliferation of atypical cells, capable of invading and spreading throughout the body, originating in diverse tissues and organs, and categorized by its cell or tissue of origin. The number of cancer cases is escalating, primarily attributed to extended life expectancy, given that the likelihood of developing cancer increases with age. Cancer gene therapy addresses cancer by either altering or substituting defective genes to halt the proliferation of cancer cells or to boost the immune system’s capacity to eliminate them. As an illustration, Macmillan Cancer Support, an organization based in the UK, reported in August 2024 that over 3 million individuals in the UK are currently living with cancer. This number is forecasted to climb to 3.5 million by 2025, 4 million by 2030, and reach 5.3 million by 2040. Consequently, the rising incidence of cancer is a key factor fueling the expansion of the cancer gene therapy market.

    Which Segment Accounts For The Largest Share In The Cancer Gene Therapy Market?

    The cancer gene therapy market covered in this report is segmented

    1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

    2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications

    3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types

    4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Diagnostic centers, Other End Users

    Subsegments:

    1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy

    2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)

    3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

    Which Long-Term Trends Will Play A Crucial Role In The Cancer Gene Therapy Market?

    Leading companies in the cancer gene therapy market are concentrating on developing advanced treatments, such as CAR-T cell therapy, to enhance therapeutic precision, improve patient outcomes, and more effectively target cancer cells while minimizing harm to healthy tissues. CAR-T therapy is an advanced form of immunotherapy where a patient’s immune cells are engineered with special receptors to better detect and destroy cancer cells. For instance, in April 2024, ImmunoACT, an India-based biotechnology company, launched NexCAR19 (actalycabtagene autoleucel), which is the country’s first indigenously developed CAR-T cell therapy for cancer. Specifically formulated to treat B-cell lymphomas and leukemias, NexCAR19 functions by reprogramming a patient’s own T cells to identify and eliminate malignant cells. Built upon advanced chimeric antigen receptor (CAR) technology, this therapy is domestically manufactured, thereby increasing its affordability and accessibility compared to imported choices. This launch signifies a crucial milestone for India’s entry into the global cancer gene therapy space, showcasing notable progress in domestic innovation and personalized cancer treatment.

    Who Are The Dominant Players In The Cancer Gene Therapy Market Today?

    Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, Biogen Inc., Sarepta Therapeutics Inc., AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, and Abeona Therapeutics Inc.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

    What Regional Factors Are Accelerating Growth In The Cancer Gene Therapy Market?

    North America was the largest region in the cancer gene therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=27233&type=smp

    Browse Through More Reports Similar to the Global Cancer Gene Therapy Market 2025, By The Business Research Company

    Mortgage Lender Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/mortgage-lender-global-market-report

    Home Insurance Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/home-insurance-global-market-report

    Mortgage Brokerage Services Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/mortgage-brokerage-services-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Breast Lesion Localization Methods Market Growth Prospects and Strategic Opportunities Through 2029

    Global Breast Lesion Localization Methods Market Growth Prospects and Strategic Opportunities Through 2029

    Uncover key drivers, emerging technologies, and competitive movements shaping the breast lesion localization methods market from 2025–2034 with trusted insights from The Business Research Company

    What CAGR And Valuation Are Anticipated For The Breast Lesion Localization Methods Market?

    The breast lesion localization methods market has experienced significant expansion recently. This market is projected to increase from $1.50 billion in 2024 to $1.67 billion by 2025, reflecting a compound annual growth rate (CAGR) of 11.0%. Historically, this growth has been driven by factors such as higher disposable incomes, enhanced awareness regarding early detection, a growing preference for minimally invasive surgeries, the wider uptake of image-guided procedures, and the increasing availability of sophisticated diagnostic tools.

    The breast lesion localization methods market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $2.50 billion by 2029, achieving a compound annual growth rate (CAGR) of 10.7%. This expansion during the forecast period is driven by an increasing aging population, rising healthcare expenditure, broader availability of reimbursement policies, a growing demand for personalized treatments, and the increased adoption of minimally invasive procedures. Significant developments expected during this period include advancements in wireless localization technologies, innovations in magnetic and radar-based localization, the integration of artificial intelligence into imaging systems, sophisticated imaging-guided surgical techniques, and the incorporation of emerging technologies.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27232&type=smp

    What Core Drivers Are Expected To Influence The Breast Lesion Localization Methods Market?

    The rising occurrence of breast cancer is projected to fuel the expansion of the breast lesion localization methods market in the future. Breast cancer is defined as a condition where breast cells multiply without regulation, resulting in a tumor frequently visible on X-rays or palpable as a lump. This increase in breast cancer diagnoses is linked to longer life expectancies, given that advancing age is a primary risk factor for developing breast tumors. Breast lesion localization methods aid breast cancer treatment by facilitating the accurate identification and marking of abnormal tissue, thereby enabling surgeons to precisely excise tumors while safeguarding healthy breast tissue. For example, as reported by the American Association for Cancer Research, a US-based nonprofit, in February 2025, approximately 2.3 million individuals received a breast cancer diagnosis, and about 670,000 succumbed to the illness worldwide in 2022. Should present trends persist, annual diagnoses could reach 3.2 million cases, with deaths potentially climbing to 1.1 million by 2050. Consequently, the growing frequency of breast cancer is propelling the demand for the breast lesion localization methods market.

    What Are The Main Segment Classifications In The Breast Lesion Localization Methods Market?

    The breast lesion localization methods market covered in this report is segmented

    1) By Type Of Localization Method: Wire Localization, Radioactive Seed Localization, Magnetic Seed Localization, Ultrasound-Guided Localization, Needle Localization

    2) By Usage: Tumor Identification, Sentinel Lymph-Node Identification, Other Usages

    3) By Technology: Radioactive, Magnetic, Radiofrequency, Other Technologies

    4) By Application: Breast Biopsy, Breast-Conserving Surgery, Neoadjuvant Therapy, Other Applications

    5) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Academic And Research Institutes

    Subsegments:

    1) By Wire Localization: Single-Hook Wire Localization, Double-Hook Wire Localization, Anchor-Shaped Wire Localization, Hooked Needle Wire Localization, Flexible Wire Localization

    2) By Radioactive Seed Localization (RSL): Iodine-125 Seed Localization, Technetium-99m Seed Localization, Dual-Isotope Seed Localization, Gamma Probe-Guided Seed Localization

    3) By Magnetic Seed Localization: Magnetic Tracer-Based Localization, Magnetic Clip Localization, Ferromagnetic Marker-Based Localization, Dual Magnetic-Marker And Ultrasound-Guided Systems

    4) By Ultrasound-Guided Localization: Conventional Ultrasound-Guided Needle Localization, Ultrasound-Guided Wire Placement, Real-Time Ultrasound-Guided Seed Placement, Contrast-Enhanced Ultrasound Localization

    5) By Needle Localization: Fine Needle Localization, Core Needle Localization, Vacuum-Assisted Needle Localization, Stereotactic-Guided Needle Localization, Palpation-Guided Needle Localization

    How Are Industry Trends Steering The Expansion Of The Breast Lesion Localization Methods Market?

    Leading companies within the breast lesion localization methods market are concentrating on creating advanced solutions, such as radar reflector localization systems, to boost the precision, patient comfort, and surgical results during breast-conserving operations. A radar reflector localization system is defined as a wire-free breast lesion localization technology that involves implanting a small radar reflector at the tumor site before surgery. For instance, in December 2022, Merit Medical Systems, Inc., a US-based manufacturer of disposable medical devices, introduced Scout Bx, a wireless, radar-guided localization system designed to assist breast surgeons in locating biopsied tumors for extraction. Scout Bx provides a variety of distinctive features aimed at improving accuracy and patient comfort in breast-conserving surgeries. In contrast to conventional wire-based localization, Scout Bx employs radar technology to precisely detect and localize biopsied tumors, allowing surgeons to plan incisions more effectively and reduce the removal of healthy tissue. Its wire-free design diminishes patient apprehension, removes scheduling challenges between radiology and surgery, and enables placement days or even weeks prior to the procedure. This system proves particularly advantageous for dense breast tissue, offering real-time surgical guidance and improved workflow efficiency.

    Which Companies Are Contributing Significantly To The Breast Lesion Localization Methods Market Growth?

    Major companies operating in the breast lesion localization methods market are Becton, Dickinson and Company, Hologic Inc., Halma Plc, Cook Medical LLC, Merit Medical Systems Inc., Argon Medical Devices Inc., Eckert & Ziegler AG, Theragenics Corporation, SOMATEX Medical Technologies GmbH, BPB Medica S.r.l., Devicor Medical Products Inc., Cianna Medical Inc., Mermaid Medical A/S, Ranfac Corporation, Sirius Medical B.V., MOLLI Surgical Inc., IsoAid LLC, STERYLAB S.r.l., MDL S.r.l., Biomedical Srl.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/breast-lesion-localization-methods-global-market-report

    Which Region Holds The Greatest Opportunity For Breast Lesion Localization Methods Market Expansion?

    North America was the largest region in the breast lesion localization methods market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast lesion localization methods market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=27232&type=smp

    Browse Through More Reports Similar to the Global Breast Lesion Localization Methods Market 2025, By The Business Research Company

    Construction And Demolition Waste Management Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/construction-and-demolition-waste-management-global-market-report

    Industrial Maintenance Services Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/industrial-maintenance-services-global-market-report

    Industrial Services Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/industrial-services-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Which Factors Will Push The Bacterial And Viral Specimen Collection Market To Achieve $39.68 Billion By 2029?

    Which Factors Will Push The Bacterial And Viral Specimen Collection Market To Achieve $39.68 Billion By 2029?

    Uncover key drivers, emerging technologies, and competitive movements shaping the bacterial and viral specimen collection market from 2025–2034 with trusted insights from The Business Research Company

    What Is The Present And Forecasted Size Of The Bacterial And Viral Specimen Collection Market?

    The bacterial and viral specimen collection market has experienced rapid growth in recent years. Its valuation is projected to increase from $20.95 billion in 2024 to $23.86 billion in 2025, advancing at a compound annual growth rate (CAGR) of 13.9%. This historical expansion can be attributed to factors such as a rising demand for accurate and early diagnosis, an increase in viral outbreak incidences, growth in government funding, a rise in global healthcare expenditure, and the expansion of telemedicine.

    The bacterial and viral specimen collection market size is projected to experience substantial growth over the next few years, expanding to $39.68 billion by 2029, achieving a compound annual growth rate (CAGR) of 13.6%. This expected expansion during the forecast period stems from the proliferation of global disease surveillance networks, increasing financial commitments towards pandemic readiness, the escalating occurrence of infectious diseases, the rising challenge of antimicrobial resistance, and an increase in bacterial infections. Significant developments anticipated in this forecast period encompass technological progress, the incorporation of digital tracking capabilities, the uptake of non-invasive methods for specimen collection, the utilization of microfluidic devices, and the implementation of automated systems for tracking specimens.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27219&type=smp

    What Underlying Factors Are Supporting The Bacterial And Viral Specimen Collection Market Growth?

    The escalating incidence of infectious diseases is poised to fuel the expansion of the bacterial and viral specimen collection market in the coming years. Infectious diseases are conditions triggered by detrimental microorganisms, including bacteria, viruses, fungi, or parasites, which can disseminate among individuals through direct or indirect contact. The primary driver behind the rising prevalence of these diseases is increasing urbanization, which fosters higher population densities and closer human proximity, thereby accelerating disease transmission and creating favorable environments for pathogens to spread more easily within communities. Bacterial and viral specimen collection plays a critical role in infectious disease management by providing essential samples that facilitate precise detection and accurate diagnosis, enabling timely and targeted medical interventions. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases saw an increase from 8,320 in 2022 to 9,615 in 2023, marking a rise of 1,295 cases, while the incidence rate escalated from 2.5 to 2.9 per 100,000 persons, highlighting a significant upward trend over the year. Consequently, the increasing prevalence of infectious diseases is directly driving the growth of the bacterial and viral specimen collection market.

    How Does The Bacterial And Viral Specimen Collection Market Differ By Segment?

    The bacterial and viral specimen collection market covered in this report is segmented

    1) By Product: Bacterial Specimen Collection, Viral Specimen Collection

    2) By Application: Diagnostics, Research

    3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End User

    Subsegments:

    1) By Bacterial Specimen Collection: Swabs, Transport Media, Culture Plates & Media, Blood Culture Bottles, Biopsy And Tissue Collection Kits, Urine Collection Containers, Other Specialized Collection Devices

    2) By Viral Specimen Collection: Viral Transport Media, Blood Collection Tubes, Saliva Collection Kits, Sputum Collection Containers, Stool Collection Kits, Other Specialized Collection Devices

    What New Opportunities Are Emerging From Trends In The Bacterial And Viral Specimen Collection Market?

    Leading firms in the bacterial and viral specimen collection market are concentrating on bringing forth innovative solutions, including viral DNA and RNA extraction kits, to boost the efficiency, precision, and pace of pathogen identification and analysis. Such a kit serves as a laboratory instrument for isolating and purifying viral genetic material from clinical specimens, enabling precise molecular testing and diagnosis. For example, in April 2024, New England Biolabs, a US-based life sciences organization, unveiled the Monarch Mag Viral DNA and RNA Extraction Kit. This magnetic bead-based purification kit is engineered for the swift, dependable, and highly sensitive extraction of viral DNA and RNA from diverse sample types, including saliva, respiratory swabs, and enriched wastewater. It accommodates both manual and automated workflows, being compatible with platforms like KingFisher Flex and Agilent Bravo, thereby facilitating high-throughput processing. The kit improves detection sensitivity for even low viral loads and incorporates carrier RNA to enhance recovery. Furthermore, it is appropriate for subsequent applications such as qPCR, RT-qPCR, ddPCR, and next-generation sequencing (NGS). Its objective is to fulfill requirements in infectious disease testing, viral genome sequencing, and environmental surveillance through scalable, hands-free workflows.

    Who Are The Global Leaders Steering The Bacterial And Viral Specimen Collection Market Forward?

    Major companies operating in the bacterial and viral specimen collection market are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Becton Dickinson and Company, Lonza Group AG, Hologic Inc., bioMérieux SA, Quidel Corporation, QIAGEN N.V., DiaSorin S.p.A., Greiner Bio-One International GmbH, Spectrum Solutions LLC, Hardy Diagnostics Inc., EKF Diagnostics Holdings Plc, Trinity Biotech Plc, Puritan Medical Products Company LLC, Wuxi NEST Biotechnology Co. Ltd., Copan Diagnostics Inc., VIRCELL S.L., Medical Wire & Equipment Co. Ltd., HiMedia Laboratories Pvt. Ltd., Longhorn Vaccines and Diagnostics LLC, and Beaver Biomedical Engineering Co. Ltd.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/bacterial-and-viral-specimen-collection-global-market-report

    Which Region Is Likely To Register The Fastest Growth In The Bacterial And Viral Specimen Collection Market?

    North America was the largest region in the bacterial and viral specimen collection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bacterial and viral specimen collection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=27219&type=smp

    Browse Through More Reports Similar to the Global Bacterial And Viral Specimen Collection Market 2025, By The Business Research Company

    Fire Protection System Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/fire-protection-system-global-market-report

    Sun Care Products Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/sun-care-products-global-market-report

    Car Care Products Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/car-care-products-market

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Artificial Ventilation And Anesthesia Masks Market Emerging Trends and Growth Drivers Through 2029 | Reach USD $2.99 Billion

    Artificial Ventilation And Anesthesia Masks Market Emerging Trends and Growth Drivers Through 2029 | Reach USD $2.99 Billion

    Uncover key drivers, emerging technologies, and competitive movements shaping the artificial ventilation and anesthesia masks market from 2025–2034 with trusted insights from The Business Research Company

    How Big Is The Artificial Ventilation And Anesthesia Masks Market Today And What Is Its Future Size?

    The artificial ventilation and anesthesia masks market has experienced significant expansion over recent years. This market is projected to expand from $2.18 billion in 2024 to $2.32 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this increase can be linked to factors such as an escalating volume of surgical procedures, the rising incidence of chronic obstructive pulmonary disease, a surge in admissions to intensive care units, heightened awareness regarding respiratory well-being, and an expanding elderly demographic.

    The market for artificial ventilation and anesthesia masks is projected to experience substantial expansion in the coming years, anticipated to reach a valuation of $2.99 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.5%. Factors driving this growth during the forecast period include a rising need for outpatient procedures, increased investment in healthcare infrastructure, the expanding use of home healthcare ventilation solutions, a growing elderly population, and an uptick in the utilization of emergency medical services. Key trends observed within the forecast timeframe encompass improvements in anesthesia mask materials, their incorporation into patient monitoring systems, breakthroughs in pediatric and ergonomic designs, ongoing research and development efforts in ventilation devices, and the increasing prevalence of single-use and disposable technologies.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27207&type=smp

    What External And Internal Drivers Are Influencing The Artificial Ventilation And Anesthesia Masks Market?

    The increasing prevalence of respiratory ailments is projected to fuel the expansion of the artificial ventilation and anesthesia mask market moving forward. Respiratory conditions encompass various medical issues impacting the respiratory system, including airways, lungs, and associated musculature. The surge in respiratory disease cases stems from extended exposure to air contamination, especially fine particulate matter and hazardous gases, which harm lung tissues, initiate inflammation, and elevate the risk of long-term conditions like asthma, bronchitis, and chronic obstructive pulmonary disease. Artificial ventilation and anesthesia masks are crucial for managing these conditions by supplying exact quantities of oxygen or anesthetic gases to patients during operations, critical care, or emergencies, thereby helping to sustain steady respiratory function. For instance, data from the Office for Health Improvement and Disparities, a UK-based government body, indicated in June 2025 that emergency admissions for respiratory diseases in England climbed by 7% between the financial years ending 2023 and 2024. This included specific rises of 9% for chronic obstructive pulmonary disease, 17% for adult asthma, and 16% for pneumonia. Consequently, the rising occurrence of respiratory diseases is a significant factor propelling the growth of the artificial ventilation and anesthesia mask market.

    How Is The Artificial Ventilation And Anesthesia Masks Market Categorized Across Applications And Types?

    The artificial ventilation and anesthesia masks market covered in this report is segmented

    1) By Type: Invasive Ventilation, Non-Invasive Ventilation

    2) By Mask Type: Disposable Masks, Reusable Masks

    3) By Application: Operating Rooms, Intensive Care Unit, Emergency Rooms, Homecare, Ambulatory Surgical Centers

    Subsegments:

    1) By Invasive Ventilation: Volume Controlled Ventilation, Pressure Controlled Ventilation, Pressure Support Ventilation, Synchronized Intermittent Mandatory Ventilation, High Frequency Oscillatory Ventilation

    2) By Non-Invasive Ventilation: Continuous Positive Airway Pressure, Bilevel Positive Airway Pressure, Volume Assured Pressure Support, Negative Pressure Ventilation, Proportional Assist Ventilation

    Who Are The Global Leaders Steering The Artificial Ventilation And Anesthesia Masks Market Forward?

    Major companies operating in the artificial ventilation and anesthesia masks market are Cardinal Health Inc., Air Liquide Medical Systems S.A., Medtronic plc, Koninklijke Philips N.V., GE Healthcare Technologies Inc., ResMed Inc., Teleflex Incorporated, Getinge AB, Fisher & Paykel Healthcare Corporation Limited, Drägerwerk AG & Co. KGaA, Ambu A/S, Hamilton Medical AG, GaleMed Corporation, Armstrong Medical Ltd., Cathwide Medical Inc., Romsons Scientific and Surgical Industries Pvt. Ltd., Trudell Medical International, Besmed Health Business Corporation, Flexicare Medical Limited, Intersurgical Ltd., O-Two Medical Technologies Inc., and Hans Rudolph Inc.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/artificial-ventilation-and-anesthesia-masks-global-market-report

    What Are The Emerging Regional Trends Driving The Artificial Ventilation And Anesthesia Masks Market?

    North America was the largest region in the artificial ventilation and anesthesia masks market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial ventilation and anesthesia masks market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=27207&type=smp

    Browse Through More Reports Similar to the Global Artificial Ventilation And Anesthesia Masks Market 2025, By The Business Research Company

    Fireproofing Materials Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/fireproofing-materials-global-market-report

    Fire Safety Equipment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/fire-safety-equipment-global-market-report

    Fire Protection System Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/fire-protection-system-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Central Nervous System Therapeutics Market 2025–2029: Competitive Insights and Opportunities

    Global Central Nervous System Therapeutics Market 2025–2029: Competitive Insights and Opportunities

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Market Value Is The Central Nervous System Therapeutics Industry Expected To Reach By 2029, Starting From 2025 Levels?

    The central nervous system therapeutics market size has seen robust expansion in recent years. It is forecast to grow from $123.53 billion in 2024 to $134.99 billion in 2025, representing a compound annual growth rate (CAGR) of 9.3%. The market’s past growth can be ascribed to an increase in neurological disorders, a rise in mental health awareness, an increase in research and development activities, a rise in demand for personalized medicine, and an increase in trade agreements.

    The central nervous system therapeutics market is projected to experience substantial expansion over the upcoming years. This market is set to reach $190.07 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.9%. This anticipated growth is driven by factors such as the rising incidence of CNS disorders, a heightened emphasis on therapeutic development, the growing occurrence of conditions like Alzheimer’s, an expanding elderly demographic, and a greater need for efficacious treatments. Key trends expected during this period encompass artificial intelligence applications in diagnostics, progress in antidepressant drug development, innovations in drug delivery systems, advancements within neurology, and the identification of biomarkers.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp

    Which Drivers Are Shaping The Central Nervous System Therapeutics Industry’s Market Share?

    The rising occurrence of mental health disorders is anticipated to propel the growth of the central nervous system therapeutics market moving forward. These conditions encompass a wide spectrum of issues that impact an individual’s thought processes, emotions, behavior, or mood, such as depression, anxiety disorders, schizophrenia, and bipolar disorder. The increasing prevalence of mental health disorders stems from heightened exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to conditions like anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics aid in treating mental health disorders by targeting specific brain chemicals and neural pathways involved in mood, behavior, and cognition. For example, in December 2025, a report from the UK-based Bristol City Council indicated that in Bristol, 66,815 patients aged 18 and over were recorded on GP practice depression registers in 2022/23, marking a 6.0% rise from 2021/22. Consequently, the increasing prevalence of mental health disorders is a key driver for the central nervous system therapeutics market’s expansion.

    What Are The Major Segments Identified In The Central Nervous System Therapeutics Market?

    The central nervous system therapeutics market covered in this report is segmented

    1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes

    2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases

    3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

    4) By Application: Hospital, Clinic, Homecare, Other Applications

    Subsegments:

    1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics

    2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents

    3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids

    4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives

    5) By Pain Relievers: Opioid Analgesics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief, Topical Agents

    6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

    Which Trends Are Impacting The Central Nervous System Therapeutics Market?

    Leading companies in the central nervous system therapeutics market are prioritizing the development of innovative solutions, such as capsid engineering, to improve targeted gene delivery, therapeutic effectiveness, and blood-brain barrier penetration for better treatment of neurological disorders. Capsid engineering involves modifying and optimizing the protein shell (capsid) of viral vectors, commonly adeno-associated viruses (AAVs), utilized in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a biotechnology company based in France, introduced coAAV CSF 01, a novel adeno-associated virus (AAV) designed for central nervous system (CNS) delivery using their proprietary ALIGATER platform. It demonstrated significantly improved transduction efficiency and safety compared to AAV9. When delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Remarkably, expression levels equivalent to AAV9 were attained at merely one-fifth of the dose, showcasing its superior potency. Additionally, the vector displayed substantially reduced off-target expression in peripheral organs such as the liver, while sustaining a favorable safety profile, including preserved peripheral nerve integrity. These results highlight the vector’s potential to enhance CNS gene therapy outcomes with greater precision and reduced systemic risk.

    Who Are The Key Multinational Companies Dominating The Central Nervous System Therapeutics Market?

    Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Kyverna Therapeutics Inc., Immunic Inc., LEXEO Therapeutics Inc., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., and Assertio Holdings Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report

    How Does The Central Nervous System Therapeutics Market Perform Across Key Geographic Regions?

    North America was the largest region in the central nervous system therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Central Nervous System Therapeutics Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=27249&type=smp

    Browse Through More Reports Similar to the Global Central Nervous System Therapeutics Market 2025, By The Business Research Company

    Coronavirus Current Therapy Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report

    Insurance Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/insurance-global-market-report

    Critical Illness Insurance Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/critical-illness-insurance-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Cell Culture Media Market For Regenerative Medicines Industry Insights: Market Forecast to 2029

    Cell Culture Media Market For Regenerative Medicines Industry Insights: Market Forecast to 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    How Much Was The Cell Culture Media Market For Regenerative Medicines Market Worth In 2025, And What Is Its Anticipated Value By 2029?

    The cell culture media market for regenerative medicines has witnessed substantial growth over recent years. It is anticipated to increase from $4.68 billion in 2024 to $5.26 billion in 2025, achieving a compound annual growth rate (CAGR) of 12.3%. This historical expansion can be ascribed to several contributing factors, including the surging demand for regenerative medicines such as cell therapies and tissue engineering, an escalating prevalence of chronic diseases that fuels research requirements, the expansion of biopharmaceutical production necessitating advanced culture systems, an uptick in government funding alongside supportive regulations for life sciences, and enhancements in media formulations and the overall efficiency of cell culture processes.

    The market for cell culture media within regenerative medicines is anticipated to experience significant expansion over the coming years. This market is projected to reach $8.24 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.9%. This expansion during the forecast period is driven by several factors, including the escalating demand for regenerative therapies and biopharmaceuticals, greater investments in regenerative medicine research and development, wider adoption of serum-free and chemically defined media, enhanced government backing and supportive regulations, and the increasing necessity for scalable and automated cell culture production systems. Key trends anticipated during this period encompass progress in serum-free and xeno-free media, the creation of automated and high-throughput cell culture systems, breakthroughs in personalized and precision therapies, advancements in stem cell and regenerative medicine applications, and the formulation of custom and chemically defined solutions.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27241&type=smp

    Which Factors And Drivers Are Influencing The Cell Culture Media Market For Regenerative Medicines Market In 2025?

    The expanding emphasis on personalized medicine is anticipated to stimulate the expansion of the cell culture media market for regenerative medicines market moving ahead. This approach, known as personalized medicine, involves tailoring medical treatments and preventive measures according to an individual’s unique genetic profile, surrounding conditions, and daily habits. The heightened attention on personalized medicine stems from a growing demand for precise therapies for rare and intricate illnesses, a demand amplified by advancements in genomic research and wider availability of accurate diagnostic tools. The cell culture media market for regenerative medicines facilitates personalized medicine by allowing for the creation of unique cell culture media designed to cultivate patient-specific cells for bespoke regenerative treatments. As an illustration, information from the Personalized Medicine Coalition, a US-based nonprofit organization, indicates that in February 2024, the FDA gave its approval to 16 new personalized treatments for patients with rare diseases in 2023, an increase from 6 approvals in 2022. Consequently, the increased attention on personalized medicine is acting as a catalyst for the expansion of the cell culture media market for regenerative medicines market.

    What Are The Different Segment Classifications Within The Cell Culture Media Market For Regenerative Medicines Market?

    The cell culture media market for regenerative medicines market covered in this report is segmented

    1) By Type: Liquid Media, Semi-Solid And Solid Media

    2) By Application: Tissue Engineering, Gene Therapy, Stem Cell Research, Cell Therapy, Drug Discovery And Development, Other Applications

    3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Hospitals And Diagnostic Laboratories, Cell Banks, Other End Users

    Subsegment:

    1) By Liquid Media: Basal Media, Serum-Free Media, Chemically Defined Media, Protein-Free Media, Specialty Media

    2) By Semi-Solid And Solid Media: Agar-Based Media, Gelatin-Based Media, Collagen-Based Media, Methylcellulose Media, Other Hydrogel-Based Media

    What Trends Are Redefining The Cell Culture Media Market For Regenerative Medicines Market Dynamics?

    Leading companies active in the cell culture media market for regenerative medicines are focused on developing innovative products, like animal-component-free mediums. These developments aim to improve cell growth consistency, increase safety, meet regulatory demands, and support scalable clinical manufacturing. An animal-component-free medium is a cell culture solution formulated entirely without materials derived from animals, designed to enhance consistency, safety, and regulatory adherence in research and therapeutic settings. For instance, in May 2023, Lonza Group AG, a Switzerland-based life sciences company, introduced TheraPEAK T-VIVO Cell Culture Medium. This is a novel, chemically defined, animal-component-free formulation created to optimize CAR T-cell manufacturing. By eliminating the reliance on animal or human serum—traditionally associated with significant variability, the risk of adventitious agents, and the requirement for extensive safety testing and batch stockpiling—the new medium boosts process consistency, enhances control, and streamlines regulatory compliance, ultimately lowering costs and accelerating time-to-market. Providing high performance without the need for human serum supplementation, TheraPEAK T-VIVO signifies a strategic step forward in Lonza’s mission to expedite and simplify cell therapy commercialization for its worldwide customer base.

    Which Key Players Are Driving Competition In The Cell Culture Media Market For Regenerative Medicines Market?

    Major companies operating in the cell culture media market for regenerative medicines market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton Dickinson and Company, GE Healthcare Technologies Inc., Corning Incorporated, Avantor Inc., Lonza Group AG, Cytiva Life Sciences, Sartorius AG, Bio-Techne Corporation, Miltenyi Biotec B.V. & Co. KG, STEMCELL Technologies Inc., FUJIFILM Irvine Scientific Inc., Takara Bio Inc., HiMedia Laboratories Private Limited, PromoCell GmbH, Cell Biologics Inc., Xcell Biosciences Inc., and Eklavya Biotech Pvt Ltd.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/cell-culture-media-market-for-regenerative-medicines-global-market-report

    What Are The Key Regional Factors Influencing The Cell Culture Media Market For Regenerative Medicines Market Growth?

    North America was the largest region in the cell culture media market for regenerative medicines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell culture media market for regenerative medicines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Cell Culture Media Market For Regenerative Medicines Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=27241&type=smp

    Browse Through More Reports Similar to the Global Cell Culture Media Market For Regenerative Medicines Market 2025, By The Business Research Company

    Real Time Payments Market 2025

    https://www.thebusinessresearchcompany.com/report/real-time-payments-market

    Payments Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/payments-global-market-report

    Digital Payments Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/digital-payments-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Cancer Gene Therapy Market Size Projected to Reach $7.67 Billion During the Forecast Period

    Global Cancer Gene Therapy Market Size Projected to Reach $7.67 Billion During the Forecast Period

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Is The Anticipated Size Of The Cancer Gene Therapy Market Over The Five-Year Period 2025–2029?

    The cancer gene therapy market size has seen rapid expansion in recent years. It is anticipated to increase from $3.61 billion in 2024 to $4.21 billion in 2025, achieving a compound annual growth rate (CAGR) of 16.6%. This historical growth is attributable to several key factors, including a rising awareness of oncovirus-related cancers, an increase in collaborations between biotechnology firms and academic institutions, heightened clinical trial activity for early-phase gene therapies, a growing demand for ex vivo modified cell therapies, and a surge in strategic licensing agreements for gene therapy platforms.

    The cancer gene therapy market size is projected to experience substantial growth in the near future, forecast to reach $7.67 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 16.2%. This anticipated expansion during the forecast period is primarily driven by an increased emphasis on non-viral delivery methods, wider access to companion diagnostics, a burgeoning interest in readily available off-the-shelf allogeneic cell therapies, the expanding role of contract development & manufacturing organizations (CDMOs), and advancements in synthetic biology facilitating customizable gene circuits. Furthermore, key trends anticipated during this period encompass progress in non-viral gene delivery platforms, enhanced manufacturing automation for gene therapy production, the creation of synthetic promoters for specific cancer expression, novel approaches in intratumoral gene therapy administration, and the formulation of multiplexed gene modulation strategies.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp

    What Are The Top Growth Drivers Impacting The Cancer Gene Therapy Market Outlook?

    A rising occurrence of cancer is anticipated to fuel the expansion of the cancer gene therapy market in the future. Cancer is characterized as a condition involving the uncontrolled multiplication of abnormal cells, which can invade and spread to various parts of the body, originating in diverse tissues and organs, and classified according to its cellular or tissue source. The growing number of cancer cases is attributed to increasing life expectancy, as the risk of developing cancer rises with age. Cancer gene therapy offers treatment by modifying or replacing faulty genes to halt cancer cell growth or to enhance the immune system’s ability to destroy them. For example, Macmillan Cancer Support, a UK-based organization, reported in August 2024 that more than 3 million people in the UK are living with cancer. This figure is projected to reach 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the increasing incidence of cancer is a key driver for the growth of the cancer gene therapy market.

    How Is The Cancer Gene Therapy Market Segmented?

    The cancer gene therapy market covered in this report is segmented

    1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

    2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications

    3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types

    4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Diagnostic centers, Other End Users

    Subsegments:

    1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy

    2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)

    3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

    Which Market Trends Are Creating New Opportunities In The Cancer Gene Therapy Industry?

    Leading companies in the cancer gene therapy market are concentrating on developing innovative treatments, such as CAR-T cell therapy, to enhance therapeutic accuracy, improve patient outcomes, and more effectively target cancer cells while minimizing harm to healthy tissues. CAR-T therapy is a sophisticated immunotherapy method where a patient’s immune cells are genetically engineered to better detect and eliminate cancer cells by integrating specialized receptors onto them. For instance, in April 2024, ImmunoACT, an India-based biotechnology company, unveiled NexCAR19 (actalycabtagene autoleucel), marking it as India’s first domestically developed CAR-T cell therapy for cancer. Specifically designed to address B-cell lymphomas and leukemias, NexCAR19 operates by reprogramming a patient’s own T cells to recognize and destroy malignant cells. Built upon advanced chimeric antigen receptor (CAR) technology, the therapy is manufactured locally, thus making it more affordable and accessible compared to imported options. This launch represents a significant milestone for India’s presence in the global cancer gene therapy arena, emphasizing notable strides in indigenous innovation and personalized cancer care.

    Which Major Firms Are Strengthening Their Position In The Cancer Gene Therapy Industry?

    Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, Biogen Inc., Sarepta Therapeutics Inc., AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, and Abeona Therapeutics Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

    What Are The Regional Market Dynamics Impacting The Cancer Gene Therapy Industry?

    North America was the largest region in the cancer gene therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Cancer Gene Therapy Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=27233&type=smp

    Browse Through More Reports Similar to the Global Cancer Gene Therapy Market 2025, By The Business Research Company

    Mortgage Lender Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/mortgage-lender-global-market-report

    Property And Casualty Insurance Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/property-and-casualty-insurance-global-market-report

    Home Insurance Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/home-insurance-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model